DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells

Biochemical and Biophysical Research Communications

Volumn 421, Issue 1, 2012, Pages 98-104

  Saiki, Yuriko ^a   Yoshino, Yuki ^a   Fujimura, Hiroko ^a   Manabe, Tatsuya ^a   Kudo, Yuki ^b   Shimada, Miki ^b,c   Mano, Nariyasu ^b,c   Nakano, Tomohiro ^a   Lee, Yoonha ^a   Shimizu, Shinjiro ^a   Oba, Shinya ^a   Fujiwara, Sho ^a   Shimizu, Hideyuki ^a   Chen, Na ^a   Nezhad, Zhaleh Kashkouli ^a   Jin, Guo ^a   Fukushige, Shinichi ^a   Sunamura, Makoto ^a,d   Ishida, Masaharu ^a   Motoi, Fuyuhiko ^a   Egawa, Shinichi ^a   Unno, Michiaki ^a   Horii, Akira ^a   more..

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

Chemoresistance; Deoxycytidine kinase (DCK); Gemcitabine; Pancreatic cancer

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; HISTONE H2AX; K RAS PROTEIN; PROTEIN P53; RNA; SMAD4 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HISTONES; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA, SMALL INTERFERING;

EID: 84860332244     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.122     Document Type: Article

References (32)

1. Matsuda T., Marugame T., Kamo K., et al. Cancer incidence and incidence rate in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) Project. Jpn. J. Clin. Oncol. 2005, 41(2011):139-147.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
3. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
4. Ishii H., Furuse J., Nagase M., et al. Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J. Gastroenterol. Hepatol. 2005, 20:62-66.
5. Bergman A.M., Pinedo H.M., Peters G.J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 2002, 5:19-33.
6. Kobari M., Matsuno S., Sato T., et al. Establishment of human pancreatic cancer cell line and detection of pancreatic cancer associated antigen. Tohoku J. Exp. Med. 1984, 143:33-46.
7. Kobari M., Hisano H., Matsuno S., et al. Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs. Tohoku J. Exp. Med. 1986, 150:231-248.
8. Amikura K., Kobari M., Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int. J. Pancreatol. 1995, 17:139-146.
9. Dexter D.L., Spremulli E.N., Fligiel Z., et al. Heterogeneity of cancer cells from a single human colon carcinoma. Am. J. Med. 1981, 71:949-956.
10. Hojo H. Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics. Niigata Igakukai Zasshi 1977, 91:737-752.
11. Saijyo S., Kudo T., Suzuki M., et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J. Exp. Med. 1995, 177:61-71.
12. Ogawa T., Ogawa K., Shiga K., et al. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2010, 267:1599-1606.
13. Sakurada A., Suzuki A., Sato M., et al. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn. J. Cancer Res. 1997, 88:1025-1028.
14. Cuny M., Kramar A., Courjal F., et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000, 60:1077-1083.
15. Galmarini C.M., Clarke M.L., Jordheim L., et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004, 4:8.
16. Giovannetti E., Del Tacca M., Mey V., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006, 66:3928-3935.
17. Ogawa K., Shiga K., Saijo S., et al. A novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma. Am. J. Med. Genet. A 2006, 140:2441-2446.
18. Sun C., Yamato T., Furukawa T., et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol. Rep. 2001, 8:89-92.
19. Yamanaka S., Gu Z., Sato M., et al. siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 2008, 75:2-8.
20. Vainchtein L.D., Rosing H., Thijssen B., et al. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:2312-2322.
21. Shimizu H., Horii A., Sunamura M., et al. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method " microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). Biochem. Biophys. Res. Commun. 2011, 411:162-167.
22. Xu S., Furukawa T., Kanai N., et al. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 2005, 50:159-167.
23. Ishida M., Sunamura M., Furukawa T., et al. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World J. Gastroenterol. 2007, 13:4593-4597.
24. Hata T., Furukawa T., Sunamura M., et al. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65:2899-2905.
25. Wong A., Soo R.A., Yong W.P., et al. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 2009, 41:77-88.
26. Huang P., Chubb S., Hertel L.W., et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991, 51:6110-6117.
27. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 2007, 6:1239-1248.
28. Ruiz van Haperen V.W., Veerman G., Eriksson S., et al. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994, 54:4138-4143.
29. Obata T., Endo Y., Tanaka M., et al. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn. J. Cancer Res. 2001, 92:793-798.
30. Veuger M.J., Honders M.W., Landegent J.E., et al. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000, 96:1517-1524.
31. Marechal R., Mackey J.R., Lai R., et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2011, 116:5200-5206.
32. Okusaka T., Funakoshi A., Furuse J., et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2008, 61:615-621.